Unicycive Therapeutics Resubmitted Drug Application
The company filed new data for its oxylanthanum carbonate treatment after receiving past FDA rejections.
Updated on Sept. 29, 2026 in Corporate Finance
Live Poll
Should federal regulators require drug makers to maintain multiple manufacturing sites for critical medications?
Unicycive Therapeutics has resubmitted its New Drug Application for oxylanthanum carbonate to the FDA. The submission includes updated Chemistry, Manufacturing, and Controls data from a new third-party vendor to address previous regulatory deficiencies.
Why it matters
The FDA previously issued Complete Response Letters to the company due to issues with third-party manufacturing. This resubmission aims to satisfy those requirements by incorporating stability study data and in-vitro bridging evidence.
Unicycive Therapeutics reported $61.4 million in cash and marketable securities as of June 30, 2026. The new manufacturing vendor completed 12-month drug product stability studies as part of the resubmission package.
The players
Unicycive Therapeutics
A biotechnology company based in Mountain View, California, that focuses on the development of therapies for kidney disease.
Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.
The details
Unicycive Therapeutics intends to maintain a redundant supply chain by utilizing both its original manufacturing partner and the new vendor. The new facility recently received a No Action Indicated status following an FDA inspection in March 2024.
Timeline
March 2024: The FDA inspected the new manufacturing vendor facility.
June 2025: The FDA issued the initial Complete Response Letter.
June 2026: The company received a second Complete Response Letter.
June 30, 2026: The company reported its cash and securities position.
September 29, 2026: The New Drug Application was officially resubmitted.
Market Landscape
This resubmission reflects the ongoing industry challenge of maintaining regulatory compliance during third-party manufacturing transitions. It follows a pattern set by the FDA Prescription Drug User Fee Act, which governs the established timelines for drug application reviews.
The company expects its current cash position to provide sufficient operational runway through the second half of 2027. Investors and stakeholders should monitor the upcoming FDA response, as it will determine the viability of bringing this medication to the 450,000 U.S. patients who require it.
The takeaway
Maintaining redundant vendor partnerships is a critical strategy for biotech firms navigating complex FDA manufacturing standards. Companies that successfully bridge data between suppliers can better ensure product stability and regulatory alignment.
What happens next
The company anticipates FDA acceptance of the resubmitted drug application within 30 days. Furthermore, a new PDUFA date is expected to be set six months from the September 29, 2026 resubmission.
Further reading
Learn more about industry regulatory milestones in the Corporate Finance section.
Live Poll
Should federal regulators require drug makers to maintain multiple manufacturing sites for critical medications?
